Item 1. Financial Statements
Item 1. Financial Statements
ONTO INNOVATION INC.
CONDENSED CONSOLIDATED S TATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)
Three Months Ended
Nine Months Ended
September 27,
September 28,
September 27,
September 28,
2025
2024
2025
2024
Revenue
$
218,193
$
252,210
$
738,397
$
723,382
Cost of revenue
107,570
115,831
362,419
340,482
Gross profit
110,623
136,379
375,978
382,900
Operating expenses:
Research and development
32,493
28,277
95,815
81,876
Sales and marketing
17,103
19,451
51,729
56,635
General and administrative
24,820
20,298
72,608
57,363
Amortization
8,445
13,114
25,336
39,338
Restructuring and other
4,074
2,167
11,421
3,046
Total operating expenses
86,935
83,307
256,909
238,258
Operating income
23,688
53,072
119,069
144,642
Interest income, net
9,290
8,667
27,187
24,524
Other (expense) income, net
( 999
)
( 724
)
( 2,879
)
10
Income before provision for income taxes
31,979
61,015
143,377
169,176
Provision for income taxes
3,755
7,964
17,147
16,323
Net income
$
28,224
$
53,051
$
126,230
$
152,853
Earnings per share:
Basic
$
0.58
$
1.07
$
2.57
$
3.10
Diluted
$
0.57
$
1.07
$
2.57
$
3.08
Weighted average number of shares outstanding:
Basic
49,023
49,426
49,044
49,333
Diluted
49,106
49,694
49,178
49,669
The accompanying notes are an integral part of these financial statements.
1
Table of Contents
ONTO INNOVATION INC.
CONDENSED CONSOLIDATED STATEM ENTS OF COMPREHENSIVE INCOME
(In thousands)
(Unaudited)
Three Months Ended
Nine Months Ended
September 27,
September 28,
September 27,
September 28,
2025
2024
2025
2024
Net income
$
28,224
$
53,051
$
126,230
$
152,853
Other comprehensive income (loss), net of tax:
Change in net unrealized gains on
available-for-sale marketable securities
191
2,162
423
1,304
Change in currency translation adjustments
( 1,864
)
4,859
7,017
270
Total other comprehensive income (loss), net of tax
( 1,673
)
7,021
7,440
1,574
Total comprehensive income
$
26,551
$
60,072
$
133,670
$
154,427
The accompanying notes are an integral part of these financial statements.
2
Table of Contents
ONTO INNOVATION INC.
CONDENSED CONSOLIDA TED BALANCE SHEETS
(In thousands)
(Unaudited)
September 27,
2025
December 28,
2024
ASSETS
Current Assets:
Cash and cash equivalents
$
603,085
$
212,945
Marketable securities
380,843
639,383
Accounts receivable, less allowance of $ 2,295 at September 27, 2025 and $ 2,585 at December 28, 2024
260,197
308,142
Inventories, net
259,370
286,979
Prepaid expenses and other current assets
41,441
30,073
Total current assets
1,544,936
1,477,522
Property, plant and equipment, net
129,071
123,868
Goodwill
330,037
329,980
Identifiable intangible assets, net
102,121
127,457
Deferred income taxes
57,203
42,811
Other assets
23,242
15,453
Total assets
$
2,186,610
$
2,117,091
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
$
52,925
$
56,261
Accrued liabilities
48,913
49,974
Deferred revenue
30,764
33,828
Other current liabilities
30,268
30,026
Total current liabilities
162,870
170,089
Deferred and other tax liabilities
4
4
Other non-current liabilities
21,670
21,116
Total liabilities
184,544
191,209
Commitments and contingencies
Stockholders’ equity:
Common stock
49
49
Additional paid-in capital
1,275,184
1,275,146
Accumulated other comprehensive loss
( 6,423
)
( 13,863
)
Accumulated earnings
733,256
664,550
Total stockholders’ equity
2,002,066
1,925,882
Total liabilities and stockholders’ equity
$
2,186,610
$
2,117,091
The accompanying notes are an integral part of these financial statements.
3
Table of Contents
ONTO INNOVATION INC.
CONDENSED CONSOLIDATED S TATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
Nine Months Ended
September 27,
September 28,
2025
2024
Cash flows from operating activities:
Net income
$
126,230
$
152,853
Adjustments to reconcile net income to net cash and cash equivalents provided by
operating activities:
Amortization of intangibles
25,336
39,338
Accretion of discount on marketable securities
( 4,292
)
( 5,353
)
Depreciation
15,174
10,818
Share-based compensation
20,378
21,826
Provision for inventory valuation
20,385
5,925
Deferred income taxes
( 14,509
)
( 15,951
)
Other, net
4,624
( 97
)
Changes in operating assets and liabilities
39,993
( 19,682
)
Net cash and cash equivalents provided by operating activities
233,319
189,677
Cash flows from investing activities:
Purchases of marketable securities
( 421,154
)
( 538,132
)
Proceeds from maturities and sales of marketable securities
684,526
342,958
Purchases of property, plant and equipment
( 23,384
)
( 27,277
)
Purchases of non-marketable equity securities
( 8,000
)
—
Acquisitions, net of cash acquired
( 57
)
—
Net cash and cash equivalents provided by (used in) investing activities
231,931
( 222,451
)
Cash flows from financing activities:
Purchases and retirement of common stock
( 75,015
)
—
Tax payments related to shares withheld for share-based compensation plans
( 12,589
)
( 18,441
)
Payment of contingent consideration for acquired business
—
( 737
)
Issuance of shares through share-based compensation plans
9,740
9,178
Net cash and cash equivalents used in financing activities
( 77,864
)
( 10,000
)
Effect of exchange rate changes on cash and cash equivalents
2,754
( 1,996
)
Net increase (decrease) in cash and cash equivalents
390,140
( 44,770
)
Cash and cash equivalents at beginning of period
212,945
233,508
Cash and cash equivalents at end of period
$
603,085
$
188,738
Supplemental disclosure of cash flow information:
Income taxes paid (net of refunds)
$
35,468
$
30,232
The accompanying notes are an integral part of these financial statements.
4
Table of Contents
ONTO INNOVATION INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands)
(Unaudited)
Common Stock
Additional
Paid-in
Accumulated
Other
Comprehensive
Accumulated
Shares
Amount
Capital
Loss
Earnings
Total
Balance at December 28, 2024
49,238
$
49
$
1,275,146
$
( 13,863
)
$
664,550
$
1,925,882
Net income
—
—
—
—
64,095
64,095
Share-based compensation
—
—
6,814
—
—
6,814
Issuance of shares through
share-based compensation
plans, net
140
—
4,179
—
—
4,179
Purchases of common stock
( 492
)
—
( 17,491
)
—
( 57,524
)
( 75,015
)
Share-based compensation plan
withholdings
( 49
)
—
( 8,684
)
—
—
( 8,684
)
Currency translation
—
—
—
2,013
—
2,013
Unrealized gain on investments
—
—
—
338
—
338
Balance at March 29, 2025
48,837
$
49
$
1,259,964
$
( 11,512
)
$
671,121
$
1,919,622
Net income
—
—
—
—
33,911
33,911
Share-based compensation
—
—
6,678
—
—
6,678
Issuance of shares through
share-based compensation
plans, net
137
—
—
—
—
—
Share-based compensation plan
withholdings
( 37
)
—
( 3,707
)
—
—
( 3,707
)
Currency translation
—
—
—
6,868
—
6,868
Unrealized loss on investments
—
—
—
( 106
)
—
( 106
)
Balance at June 28, 2025
48,937
$
49
$
1,262,935
$
( 4,750
)
$
705,032
$
1,963,266
Net income
—
—
—
—
28,224
28,224
Share-based compensation
—
—
6,886
—
—
6,886
Issuance of shares through
share-based compensation
plans, net
76
—
5,561
—
—
5,561
Share-based compensation plan
withholdings
( 4
)
—
( 198
)
—
—
( 198
)
Currency translation
—
—
—
( 1,864
)
—
( 1,864
)
Unrealized gain on investments
—
—
—
191
—
191
Balance at September 27, 2025
49,009
$
49
$
1,275,184
$
( 6,423
)
$
733,256
$
2,002,066
5
Table of Contents
Common Stock
Additional
Paid-in
Accumulated
Other
Comprehensive
Accumulated
Shares
Amount
Capital
Loss
Earnings
Total
Balance at December 30, 2023
49,086
$
49
$
1,262,029
$
( 7,899
)
$
482,356
$
1,736,535
Net income
—
—
—
—
46,853
46,853
Share-based compensation
—
—
6,486
—
—
6,486
Issuance of shares through
share-based compensation
plans, net
169
—
4,015
—
—
4,015
Share-based compensation plan
withholdings
( 53
)
—
( 9,088
)
—
—
( 9,088
)
Currency translation
—
—
—
( 2,593
)
—
( 2,593
)
Unrealized loss on investments
—
—
—
( 657
)
—
( 657
)
Balance at March 30, 2024
49,202
$
49
$
1,263,442
$
( 11,149
)
$
529,209
$
1,781,551
Net income
—
—
—
—
52,949
52,949
Share-based compensation
—
—
8,244
—
—
8,244
Issuance of shares through
share-based compensation
plans, net
181
—
—
—
—
—
Share-based compensation plan
withholdings
( 44
)
—
( 8,871
)
—
—
( 8,871
)
Currency translation
—
—
—
( 1,996
)
—
( 1,996
)
Unrealized loss on investments
—
—
—
( 201
)
—
( 201
)
Balance at June 29, 2024
49,339
$
49
$
1,262,815
$
( 13,346
)
$
582,158
$
1,831,676
Net income
—
—
—
—
53,051
53,051
Share-based compensation
—
—
7,096
—
—
7,096
Issuance of shares through
share-based compensation
plans, net
53
—
5,163
—
—
5,163
Purchases and retirement of common stock
—
—
—
—
—
—
Share-based compensation plan
withholdings
( 2
)
—
( 482
)
—
—
( 482
)
Currency translation
—
—
—
4,859
—
4,859
Unrealized gain on investments
—
—
—
2,162
—
2,162
Balance at September 28, 2024
$
49,390
$
49
$
1,274,592
$
( 6,325
)
$
635,209
$
1,903,525
The accompanying notes are an integral part of these financial statements.
6
Table of Contents
ONTO INNOVATION INC.
NOTES TO CONDENSED CONSOLI DATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1. Basis of Presentation
The accompanying interim unaudited Condensed Consolidated Financial Statements have been prepared by Onto Innovation Inc. (together with its consolidated subsidiaries, unless otherwise specified or suggested by the context, the “Company,” “Onto Innovation,” “we,” “our” or “us”) and in the opinion of management reflect all adjustments, consisting of normal recurring accruals, necessary for their fair presentation in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain reclassifications have been made to prior-period amounts to conform to current-period presentation. Preparing financial statements requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ materially from reported amounts. The interim results for the three and nine-month periods ended September 27, 2025 are not necessarily indicative of results to be expected for the entire year or any future periods. This interim financial information should be read in conjunction with the financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 28, 2024 (the “2024 Form 10-K”) filed with the Securities and Exchange Commission on February 25, 2025. The accompanying Condensed Consolidated Balance Sheet at December 28, 2024 has been derived from the audited consolidated financial statements included in the 2024 Form 10-K.
The Company operates on a 52- or 53-week fiscal year ending on the Saturday closest to December 31. Our fiscal year ending January 3, 2026 (“fiscal year 2025”) is a 53-week fiscal year. The first quarter of the Company’s fiscal year 2025 ended on March 29, 2025, the second quarter ended on June 28, 2025 and the third quarter ended on September 27, 2025. Our fiscal year ended December 28, 2024 was a 52-week fiscal year. The third quarter of the fiscal year ended December 28, 2024 ended on September 28, 2024.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates made by management include excess and obsolete inventory, fair value of assets acquired and liabilities assumed in a business combination, recoverability and useful lives of property, plant and equipment and identifiable intangible assets, recoverability of goodwill, recoverability of deferred tax assets, allowance for credit losses, liabilities for product warranty, share-based payments and liabilities for tax uncertainties. Actual results could differ from those estimates.
These estimates and assumptions are based on historical experience and on various other factors which the Company believes to be reasonable under the circumstances. The Company may engage third-party valuation specialists to assist with estimates related to the valuation of financial instruments, assets and stock awards associated with various contractual arrangements. Such estimates often require the selection of appropriate valuation methodologies and significant judgment. Actual results could differ from these estimates under different assumptions or circumstances and such differences could be material.
Recent Accounting Pronouncements
Updates Not Yet Effective
In September 2025, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2025-06, Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which removes all references to software development stages and clarifies the threshold entities apply to begin capitalizing costs. ASU No. 2025-06 is effective for annual periods beginning after December 15, 2027 and interim reporting periods within those annual reporting periods. The ASU may be applied prospectively, retrospectively or through a modified transition approach with early adoption permitted. The Company is currently evaluating the potential impact of this standard on its consolidated financial statements.
7
Table of Contents
In July 2025, the FASB issued ASU No. 2025-05, Financial Instruments - Credit Losses (Topic 326), which simplifies the estimation of credit losses on current accounts receivable and current contract assets arising from transactions accounted for under Accounting Standards Codification 606, Revenue from Contracts with Customers. The guidance allows all entities to use a practical expedient to assume that the current conditions as of the balance sheet date will remain unchanged for the remaining life of the asset when developing a reasonable and supportable forecast as part of estimating expected credit losses on these assets. The guidance is effective for fiscal years beginning after December 15, 2025, and interim periods within those fiscal years. Early adoption is permitted. Entities that elect the practical expedient are required to apply the amendments prospectively. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.
Other than the standards listed above, there have been no recent accounting pronouncements or changes in accounting pronouncements during the three and nine months ended September 27, 2025 , as compared to the recent accounting pronouncements described in the 2024 Form 10-K, that are of significance, or potential significance, to the Company.
NOTE 2. Acquisitions
Proposed Acquisition
On June 27, 2025, we entered into an Equity Purchase Agreement (the “Purchase Agreement”) to acquire all the outstanding membership interests of Semilab USA LLC (“Semilab USA”) from Semilab International Zrt. (“Semilab”), for $ 475.0 million in cash (subject to certain customary purchase price adjustments) and 706,215 shares of the Company’s common stock (the “Transaction”) . On September 25, 2025, each of the Company and Semilab received a request for additional information and documentary material (a “Second Request”) from the U.S. Department of Justice in connection with the Transaction. In response to the Second Request, and in order to increase the likelihood of a timely closing for the Transaction, on October 9, 2025, the parties entered into an amendment to the Purchase Agreement (the “Purchase Agreement Amendment”), pursuant to which the parties agreed that the Fourier-Transform infrared spectroscopy reflectometry systems business conducted by Semilab and its affiliates would not be included in the Transaction and would instead be retained by Semilab. The Purchase Agreement Amendment amends the purchase price that the Company will pay to Semilab in the transaction to $432.3 million in cash (subject to certain customary purchase price adjustments) and 641,771 shares of the Company’s common stock, par value $0.001 per share. This represents a reduction of approximately $50.0 million in total Transaction value to approximately $495.0 million based upon the closing value of the Company’s common stock on June 27, 2025. The Company continues to anticipate that the Transaction will be completed in 2025.
For the three and nine months ended September 27, 2025 , the Company incurred $ 2.1 million and $ 4.6 million of Transaction-related costs, respectively, in each case recorded within the caption “General and administrative” in the Company’s Condensed Consolidated Statements of Operations.
NOTE 3. Fair Value Measurements
Fair Value of Financial Instruments
The Company has evaluated the estimated fair value of financial instruments using available market information and valuations as provided by third-party sources. The use of different market assumptions and/or estimation methodologies could have a significant effect on the estimated fair value amounts. The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximates fair value because of the short-term maturity of these instruments.
Fair Value Hierarchy
The Company applies a three-level valuation hierarchy for fair value measurements. This hierarchy prioritizes the inputs into three broad levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the asset or liability. Level 3 inputs are unobservable inputs based on management’s assumptions used to measure assets and liabilities at fair value. A financial
8
Table of Contents
asset’s or liability’s fair value measurement classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.
The following tables provide the assets and liabilities carried at fair value measured on a recurring basis at September 27, 2025 and December 28, 2024:
Fair Value Measurements Using
Significant Other Observable
Inputs (Level 2)
September 27,
2025
December 28,
2024
(in thousands)
Assets:
Available-for-sale debt securities:
Government notes and bonds
$
197,257
$
284,863
Certificates of deposit
60,621
73,421
Commercial paper
50,922
136,557
Corporate bonds
72,043
144,542
Foreign currency forward contracts
67
61
Total assets
$
380,910
$
639,444
Available-for-sale debt securities classified as Level 2 are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. The foreign currency forward contracts are primarily measured based on the foreign currency spot and forward rates quoted by the banks or foreign currency dealers. Investment prices are obtained from third-party pricing providers, which model prices utilizing the above observable inputs, for each asset class.
See Note 4 for additional discussion regarding the fair value of the Company’s marketable securities.
Non-recurring Fair Value Measurements
During the nine-month period ended September 27, 2025 , the Company invested $ 8.0 million in the equity of a privately-held company. There were no such investments at December 28, 2024. This non-marketable equity investment is recorded at fair value on a non-recurring basis and is classified as a Level 3 asset in “Other assets” on the Condensed Consolidated Balance Sheets. This non-marketable equity investment is generally accounted for under the measurement alternative, defined as cost, less impairments, adjusted for subsequent observable price changes and is periodically assessed for impairment when events or circumstances indicate that decline in value may have occurred. As of September 27, 2025 , there have been no impairments recorded for the non-marketable equity investment.
9
Table of Contents
NOTE 4. Marketable Securities
At September 27, 2025 and December 28, 2024, marketable securities are categorized as follows:
Amortized Cost
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses
Fair Value
(in thousands)
September 27, 2025
Government notes and bonds
$
196,607
$
669
$
19
$
197,257
Certificates of deposit
60,570
51
—
60,621
Commercial paper
50,910
15
3
50,922
Corporate bonds
71,818
225
—
72,043
Total marketable securities
$
379,905
$
960
$
22
$
380,843
December 28, 2024
Government notes and bonds
$
284,763
$
387
$
287
$
284,863
Certificates of deposit
73,390
49
18
73,421
Commercial paper
136,496
103
42
136,557
Corporate bonds
144,331
283
72
144,542
Total marketable securities
$
638,980
$
822
$
419
$
639,383
The amortized cost and estimated fair value of marketable securities classified by the maturity date listed on the security, regardless of the Condensed Consolidated Balance Sheets classification, are as follows at September 27, 2025 and December 28, 2024:
September 27, 2025
December 28, 2024
Amortized Cost
Fair Value
Amortized Cost
Fair Value
(in thousands)
Due within one year
$
288,860
$
289,282
$
432,088
$
432,616
Due after one through five years
91,045
91,561
140,917
140,792
Due after five through ten years
—
—
235
235
Due after ten years
—
—
65,740
65,740
Total marketable securities
$
379,905
$
380,843
$
638,980
$
639,383
The Company has evaluated its investment policies and determined that all of its marketable securities, which are comprised of debt securities, are to be classified as available-for-sale. The Company’s available-for-sale debt securities are carried at fair value, with the unrealized gains and losses reported in Stockholders’ equity under the caption “Accumulated other comprehensive loss.” Gross realized gains and losses on available-for-sale securities are included in “Other (expense) income, net” on the Condensed Consolidated Statements of Operations and were not material during the three and nine-months ended September 27, 2025 and September 28, 2024. The Company records credit losses for its available-for-sale debt securities when it intends to sell the securities, it is more likely than not that it will be required to sell the securities before a recovery, or when it does not expect to recover the entire amortized cost basis of the securities. The cost of securities sold is based on the specific identification method.
The Company has determined that the gross unrealized losses on its marketable securities at September 27, 2025 and December 28, 2024 are temporary in nature. The Company regularly reviews its investment portfolio to identify and evaluate marketable securities that have indications of possible impairment from credit losses or other factors. Factors considered in determining whether an unrealized loss is considered to be a credit loss include the length of time and extent to which fair value has been less than the cost basis, credit quality and the Company’s ability and intent to hold the securities for a period of time sufficient to allow for any anticipated recovery in market value.
10
Table of Contents
The following table summarizes the estimated fair value and gross unrealized holding losses of marketable securities, aggregated by investment instrument and period of time in an unrealized loss position, at September 27, 2025 and December 28, 2024:
In Unrealized Loss Position For
Less Than 12 Months
In Unrealized Loss Position For
Greater Than 12 Months
Fair Value
Gross Unrealized Losses
Fair Value
Gross Unrealized Losses
(in thousands)
September 27, 2025
Government notes and bonds
$
11,152
$
11
$
3,573
$
9
Certificates of deposit
—
—
2,000
—
Commercial paper
14,597
1
8,457
1
Corporate bonds
—
—
—
—
Total
$
25,749
$
12
$
14,030
$
10
December 28, 2024
Government notes and bonds
$
37,636
$
287
$
—
$
—
Certificates of deposit
8,260
18
—
—
Commercial paper
18,317
42
—
—
Corporate bonds
13,260
71
3,200
1
Total
$
77,473
$
418
$
3,200
$
1
See Note 3 for additional discussion regarding the fair value of the Company’s marketable securities.
NOTE 5. Derivative Instruments and Hedging Activities
The Company, when it considers it to be appropriate, enters into forward contracts to hedge the economic exposures arising from foreign currency denominated transactions. These contracts are typically denominated in euro, Chinese renminbi, Japanese yen, Korean won, Singapore dollars, and Taiwanese dollars. Foreign currency forward contracts are not designated as hedges for accounting purposes, and therefore, the change in fair value is recorded in “Other (expense) income, net,” in the Condensed Consolidated Statements of Operations. The Company records its forward contracts at fair value in either “Prepaid expenses and other current assets” or “Other current liabilities” in the Condensed Consolidated Balance Sheets.
The dollar equivalent of the U.S. dollar forward contracts and related fair values as of September 27, 2025 and December 28, 2024 were as follows:
September 27, 2025
December 28, 2024
(in thousands)
Notional amount
$
45,105
$
45,883
Fair value of asset
$
67
$
61
11
Table of Contents
NOTE 6. Goodwill and Purchased Intangible Assets
Goodwill
The changes in the carrying amount of goodwill are as follows:
Nine Months Ended
September 27,
September 28,
2025
2024
(in thousands)
Balance, beginning of the period
$
329,980
$
315,811
Adjustment for previously acquired business
57
—
Balance, end of the period
$
330,037
$
315,811
Purchased Intangible Assets
Purchased intangible assets as of September 27, 2025 and December 28, 2024 are as follows:
Gross Carrying Amount
Accumulated Amortization
Net
(in thousands)
September 27, 2025
Finite-lived intangibles:
Developed technology
$
277,416
$
208,718
$
68,698
Customer and distributor relationships
66,621
36,110
30,511
Trademarks and trade names
14,171
11,259
2,912
Total identifiable intangible assets
$
358,208
$
256,087
$
102,121
December 28, 2024
Finite-lived intangibles:
Developed technology
$
387,716
$
298,013
$
89,703
Customer and distributor relationships
73,321
39,370
33,951
Trademarks and trade names
14,171
10,368
3,803
Total identifiable intangible assets
$
475,208
$
347,751
$
127,457
During the nine months ended September 27, 2025, the Company disposed of fully amortized identifiable intangible assets whose gross carrying value totaled $ 117 m illion. There were no disposals of identifiable intangible assets during the three and nine months ended September 28, 2024 .
Assuming no change in the gross carrying value of identifiable intangible assets and estimated lives, future estimated amortization expenses are:
Expected Amortization
Expense
Fiscal Year:
(in thousands)
2025 (remainder)
$
8,445
2026
32,588
2027
24,367
2028
13,482
2029
6,232
2030
6,109
Thereafter
10,898
Total
$
102,121
12
Table of Contents
NOTE 7. Balance Sheet Components
Inventories
Inventories, net are comprised of the following:
September 27, 2025
December 28, 2024
(in thousands)
Materials
$
185,709
$
176,814
Work-in-process
54,283
91,672
Finished goods
19,378
18,493
Total inventories, net
$
259,370
$
286,979
Property, Plant and Equipment
Property, plant and equipment, net is comprised of the following:
September 27, 2025
December 28, 2024
(in thousands)
Machinery and equipment
$
94,716
$
86,317
Land and building
47,611
46,583
Computer equipment and software
40,123
32,755
Leasehold improvements
22,639
20,405
Furniture and fixtures
3,922
4,081
Total property, plant and equipment, gross
209,011
190,141
Accumulated depreciation
( 79,940
)
( 66,273
)
Total property, plant and equipment, net
$
129,071
$
123,868
Other assets
Other assets are comprised of the following:
September 27, 2025
December 28, 2024
(in thousands)
Operating lease right-of-use assets
$
13,044
$
13,939
Non-marketable equity securities
8,000
—
Other
2,198
1,514
Total other assets
$
23,242
$
15,453
Accrued liabilities
Accrued liabilities are comprised of the following:
September 27, 2025
December 28, 2024
(in thousands)
Payroll and related expenses
$
37,667
$
39,850
Warranty
11,194
10,075
Other
52
49
Total accrued liabilities
$
48,913
$
49,974
13
Table of Contents
Other current liabilities
Other current liabilities are comprised of the following:
September 27, 2025
December 28, 2024
(in thousands)
Customer deposits
$
6,501
$
10,700
Current operating lease obligations
5,625
5,416
Income tax payable
4,002
8,492
Accrued professional fees
2,821
618
Other accrued taxes
7,017
839
Other
4,302
3,961
Total other current liabilities
$
30,268
$
30,026
Other non-current liabilities
Other non-current liabilities are comprised of the following:
September 27, 2025
December 28, 2024
(in thousands)
Non-current operating lease obligations
$
8,442
$
9,743
Unrecognized tax benefits (including interest)
6,320
5,489
Deferred revenue
5,853
4,009
Other
1,055
1,875
Total other non-current liabilities
$
21,670
$
21,116
NOTE 8. Commitments and Contingencies
Intellectual Property Indemnification Obligations
The Company has entered into agreements with customers that include limited intellectual property indemnification obligations that are customary in the industry. These agreements generally require the Company to compensate the other party for certain damages and costs incurred as a result of third-party intellectual property claims. The nature of the intellectual property indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay to its customers. Historically, the Company has not made any indemnification payments under such agreements and no amount has been accrued in the accompanying Condensed Consolidated Financial Statements with respect to these indemnification obligations.
Warranty Reserves
The Company generally provides a warranty on its products for a period of 12 to 14 months against defects in material and workmanship. The Company estimates the costs that may be incurred during the warranty period and records a liability in the amount of such costs at the time revenue is recognized. The Company’s estimate is based primarily on historical experience. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. Warranty provisions are generally related to current period sales. Settlements of warranty reserves are generally associated with sales that occurred during the 12 to 14 months prior to the period-end.
14
Table of Contents
Changes in the Company’s warranty reserves are as follows:
Nine Months Ended
September 27,
September 28,
2025
2024
(in thousands)
Balance, beginning of the period
$
10,858
$
9,380
Accruals
9,858
8,756
Usage
( 9,522
)
( 7,998
)
Balance, end of the period
$
11,194
$
10,138
Warranty reserves are reported in the Condensed Consolidated Balance Sheets under the captions “Accrued liabilities” and “Other non-current liabilities.”
Legal Matters
From time to time, the Company is subject to legal proceedings and claims in the ordinary course of business. In the opinion of management, any potential liabilities resulting from any current disputes would not have a material adverse effect on the Company’s unaudited interim condensed consolidated financial statements.
Line of Credit
The Company has a credit agreement with a bank that provides for a variable-rate line of credit which is secured by the marketable securities the Company has with the bank. The Company is permitted to borrow up to 70 % of the value of eligible securities held at the time the line of credit is accessed, up to a maximum of $ 100.0 million. The available line of credit as of September 27, 2025 was $ 100.0 million with an available interest rate of 4.8 %. The credit agreement is available to the Company until such time that either party terminates the arrangement at their discretion. The Company has not utilized the line of credit as of the date of this filing.
NOTE 9. Revenue
The following table represents a disaggregation of revenue by timing of revenue:
Three Months Ended
Nine Months Ended
September 27,
September 28,
September 27,
September 28,
2025
2024
2025
2024
(in thousands)
Point-in-time
$
199,831
$
237,935
$
686,524
$
679,517
Over-time
18,362
14,275
51,873
43,865
Total revenue
$
218,193
$
252,210
$
738,397
$
723,382
See Note 15 for additional discussion of the Company’s disaggregated revenue in detail.
Contract Assets and Contract Liabilities
Contract assets consist of amounts we have not invoiced but have completed the related performance obligation. These amounts generally arise from variances between the contractual payment terms and the transaction price assigned to the open performance obligations (e.g., we have recognized revenue in an amount greater than the amount that is billable under the contract). The contract assets amounts are recorded in “Accounts receivable” in the Condensed Consolidated Balance Sheets. As of September 27, 2025 and December 28, 2024, the Company had contract assets of $ 3.4 million and $ 10.1 million, respectively.
The Company records contract liabilities when the customer has been billed in advance of the Company completing its performance obligations primarily with respect to liabilities related to service contracts and installation. For contracts that have a duration of one year or less, these amounts are recorded as “Deferred revenue” in the Condensed Consolidated Balance Sheets. For contracts with a duration longer than one year, deferred revenue is recorded in “Other non-current liabilities” in the Condensed Consolidated Balance Sheets. As of September 27, 2025 and December 28, 2024, the Company carried a long-term deferred
15
Table of Contents
revenue balance of $ 5.9 million and $ 4.0 million, respectively, within “Other non-current liabilities” in the Condensed Consolidated Balance Sheets.
Changes in deferred revenue were as follows:
Three Months Ended
Nine Months Ended
September 27,
September 28,
September 27,
September 28,
2025
2024
2025
2024
(in thousands)
Balance, beginning of the period
$
43,545
$
31,281
$
37,836
$
27,225
Deferral of revenue
14,190
15,926
65,806
50,601
Recognition of current year deferred revenue
( 10,937
)
( 13,173
)
( 40,124
)
( 33,416
)
Recognition of prior period deferred revenue
( 10,181
)
( 4,068
)
( 26,901
)
( 14,444
)
Balance, end of the period
$
36,617
$
29,966
$
36,617
$
29,966
NOTE 10. Share-Based Compensation
The following table presents the detail of share-based compensation expense amounts included in the Company’s Condensed Consolidated Statement of Operations:
Three Months Ended
Nine Months Ended
September 27,
September 28,
September 27,
September 28,
2025
2024
2025
2024
(in thousands)
Cost of revenue
$
1,028
$
1,184
$
3,030
$
3,728
Research and development
1,203
1,118
3,557
4,381
Sales and marketing
1,039
1,499
3,029
4,285
General and administrative
3,617
3,294
10,284
9,432
Restructuring and other
—
—
478
—
Total share-based compensation expense
$
6,887
$
7,095
$
20,378
$
21,826
As of September 27, 2025 , there was $ 44.1 million of total unrecognized compensation cost related to restricted stock units granted under the Company’s stock plans. That cost is expected to be recognized over a weighted average period of 2.0 years following September 27, 2025.
16
Table of Contents
Equity Awards
The Company granted the following restricted stock units (“RSUs” and each, an “RSU”) and market-based performance restricted stock units (“PSUs” and each, a “PSU”) during the nine months ended September 27, 2025:
Awards Granted To:
Type of Award
Number of Shares
(in thousands)
Weighted Average
Grant Date Fair Value
Per Share
Directors
RSU (1)
13
$
94.62
Various executives and employees
RSU (2)
294
$
101.65
Various executives
PSU (3)
49
$
140.94
(1) These awards cliff vest one year from the grant date on May 21, 2026.
(2) These awards generally vest ratably over three years, one third per year beginning on the first anniversary of the grant date. These RSUs will fully vest on various dates between December 2027 and June 2028.
(3) These awards include PSUs with market performance conditions that will be evaluated relative to the performance of certain peers as defined in the award agreement. The number of units that ultimately vest on March 3, 2027 and March 3, 2028 will range from 0% to 200%, depending on achievement of these performance criteria. Total grant date value of these PSUs is approximately $6.9 million and was valued using the Monte Carlo method.
NOTE 11. Other (Expense) Income, Net
Other (expense) income, net, is comprised of the following:
Three Months Ended
Nine Months Ended
September 27,
September 28,
September 27,
September 28,
2025
2024
2025
2024
(in thousands)
Foreign currency exchange losses, net
$
( 397
)
$
( 704
)
$
( 2,308
)
$
( 115
)
Other
( 602
)
( 20
)
( 571
)
125
Total other (expense) income, net
$
( 999
)
$
( 724
)
$
( 2,879
)
$
10
NOTE 12. Income Taxes
The following table provides details of income taxes:
Three Months Ended
Nine Months Ended
September 27,
September 28,
September 27,
September 28,
2025
2024
2025
2024
(in thousands)
Income before provision for income taxes
$
31,979
$
61,015
$
143,377
$
169,176
Provision for income taxes
$
3,755
$
7,964
$
17,147
$
16,323
Effective tax rate
12
%
13
%
12
%
10
%
The income tax provision for the three and nine months ended September 27, 2025 was computed based on the Company’s annual forecast of profit by jurisdiction and forecasted effective tax rate for the year. The decrease in the Company’s income tax provision for the three months ended September 27, 2025 compared to the three months ended September 28, 2024 was primarily due to lower profitability before taxes. The increase in the Company’s income tax provision for the nine months ended September 27, 2025 compared to the nine months ended September 28, 2024 was primarily due to fewer excess tax benefits associated with equity compensation. The Company’s recorded effective tax rate for the periods presented is less than the U.S. statutory rate primarily due to projected Foreign Derived Intangible Income deductions, federal research and development tax credits, and excess tax benefits associated with equity compensation.
17
Table of Contents
The Company currently has a partial valuation allowance recorded against certain foreign and state net operating loss and credit carryforwards where the unrealizability of such deferred tax assets is more likely than not. Each quarter, the Company assesses the likelihood that it will be able to recover its deferred tax assets. The Company considers available evidence, both positive and negative, including forecasted earnings, in assessing its need for a valuation allowance. As a result of the Company’s analysis, it concluded that it is more likely than not that a portion of its deferred tax assets will not be realized. Therefore, the Company continues to provide a valuation allowance against certain deferred tax assets. The Company continues to monitor available evidence and may reverse some or all of its remaining valuation allowance in future periods, if appropriate. The Company has a recorded valuation allowance against a certain portion of its deferred tax assets of $ 12.2 million at each of September 27, 2025 and December 28, 2024.
The Organization for Economic Co-operation and Development (“OECD”) has been working on a Base Erosion and Profits Shifting (“BEPS”) project that would change various aspects of the existing framework under which the Company’s tax obligations are determined in many of the countries in which we operate. As part of the BEPS project, the OECD issued policies aimed to modernize global tax systems, including a country-by-country 15% minimum effective tax rate (“Pillar Two”) for multinational companies. Numerous countries have enacted, or are in the process of enacting, legislation to implement the Pillar Two model rules with a subset of the rules becoming effective during the current year, and the remaining rules becoming effective in later periods. In June 2025, the Group of Seven (“G7”) countries (Canada, France, Germany, Italy, Japan, the U.K. and the United States) agreed to exclude U.S. Multi-National entities (MNEs) from certain aspects of Pillar Two (the “G7 Statement”) in exchange for the United States not imposing retaliatory taxes through the One Big Beautiful Bill Act. We will continue to monitor the G7 Statement, which has not yet been incorporated into the OECD framework. At this point in time, the Company does not expect any material tax impact associated with Pillar Two rules in the countries where it operates. As these rules continue to evolve with new legislation and guidance, the Company will continue to monitor and account for the enactment of Pillar Two and the potential impacts such rules may have on its effective tax rate and cash flows in future years.
On July 4, 2025, the United States enacted tax reform legislation through the One Big Beautiful Bill Act. Included in this legislation are provisions that allow for the immediate expensing of domestic U.S. research and development expenses, immediate expensing of certain capital expenditures, and other changes to the U.S. taxation of profits derived from foreign operations. The impact of the Act has been accounted for in the provision for taxes for the quarter ended September 27, 2025 and the amount is determined to be immaterial. The Company continues to evaluate the impact the new legislation will have on the Consolidated Financial Statements for future years. However, as the assessment is ongoing, the Company is not able to quantify the impact at this time.
NOTE 13. Earnings Per Share
Basic earnings per share is calculated using the weighted average number of shares of common stock outstanding during the period. Restricted stock units and employee stock purchase grants are included in the calculation of diluted earnings per share, except when their effect would be anti-dilutive. For the three and nine months ended September 27, 2025, the weighted average number of restricted stock units excluded from the computation of diluted earnings per share we re 101 thousand and 80 thousand, respectively. Anti-dilutive shares for the three and nine months ended September 28, 2024 were immaterial.
18
Table of Contents
The Company’s basic and diluted earnings per share amounts are as follows:
Three Months Ended
Nine Months Ended
September 27,
September 28,
September 27,
September 28,
2025
2024
2025
2024
(in thousands, except for per share data)
Numerator:
Net income
$
28,224
$
53,051
$
126,230
$
152,853
Denominator:
Basic earnings per share - weighted average shares
outstanding
49,023
49,426
49,044
49,333
Effect of potential dilutive securities:
Restricted stock units and employee stock
purchase grants - dilutive shares
83
268
134
336
Diluted earnings per share - weighted average shares
outstanding
49,106
49,694
49,178
49,669
Earnings per share:
Basic
$
0.58
$
1.07
$
2.57
$
3.10
Diluted
$
0.57
$
1.07
$
2.57
$
3.08
NOTE 14. Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive loss, net of tax, were as follows:
Foreign currency
translation
adjustments
Net unrealized gains on
available-for-sale marketable
securities
Accumulated other
comprehensive loss
(in thousands)
Balance at December 28, 2024
$
( 14,491
)
$
628
$
( 13,863
)
Net current period other comprehensive income (loss)
7,017
423
7,440
Balance at September 27, 2025
$
( 7,474
)
$
1,051
$
( 6,423
)
Foreign currency
translation
adjustments
Net unrealized gains on
available-for-sale marketable
securities
Accumulated other
comprehensive loss
(in thousands)
Balance at December 30, 2023
$
( 8,664
)
$
765
$
( 7,899
)
Net current period other comprehensive income
270
1,304
1,574
Balance at September 28, 2024
$
( 8,394
)
$
2,069
$
( 6,325
)
For the nine-month period ended September 27, 2025, tax effects on net income of amounts recorded in other comprehensive income was $ 117 t housand. For the nine-month period ended September 28, 2024, tax effects on net income of amounts recorded in other comprehensive loss was $ 358 thousand .
NOTE 15. Segment Reporting and Geographic Information
The Company is organized and operates as one operating and reportable segment; the design, development, manufacture and support of high-performance control metrology, defect inspection, lithography and data analysis systems used by microelectronics device manufacturers. This determination is based on the management approach which designates internal information regularly available to the Chief Operating Decision Maker (“CODM”) for making decisions and assessing performance as the source of determination of the Company’s reportable segments. The Company’s CODM, the Chief Executive Officer, reviews financial information presented on a consolidated basis for the purpose of making operating decisions and assessing financial performance.
19
Table of Contents
The CODM uses net income as the measure of profit or loss to allocate resources and assess performance. The CODM regularly reviews net income as reported on the Company’s consolidated statements of operations. Financial forecasts and budget to actual results used by the CODM to assess performance and allocate resources, as well as those used for strategic decisions related to headcount and capital expenditures are also reviewed on a consolidated basis. The CODM considers the impact of the significant segment expenses in the table below on net income when deciding whether to reinvest profits, propose share repurchase, or pursue strategic mergers and acquisitions.
The measure of segment assets is reported on the balance sheet as total assets. The CODM does not review segment assets at a level other than that presented in the Company’s consolidated balance sheets.
The table below presents the Company’s consolidated operating results including significant segment expenses:
Three Months Ended
Nine Months Ended
September 27,
September 28,
September 27,
September 28,
2025
2024
2025
2024
(in thousands)
Revenue
$
218,193
$
252,210
$
738,397
$
723,382
Less:
Adjusted cost of revenue (1)
100,267
114,712
335,289
337,802
Adjusted research and development (2)
32,492
28,199
96,505
81,639
Adjusted sales and marketing (2)
17,103
19,411
51,729
56,515
Adjusted general and administrative (3)
22,274
19,889
66,707
55,598
Other segment items:
Restructuring and other (4)
11,377
3,251
38,550
5,621
Merger and acquisitions related (4)
2,547
562
5,212
2,200
Litigation (4)
—
—
—
27
Amortization
8,445
13,114
25,336
39,338
Operating income
23,688
53,072
119,069
144,642
Interest income, net
9,290
8,667
27,187
24,524
Other (expense) income, net
( 999
)
( 724
)
( 2,879
)
10
Provision for income taxes
3,755
7,964
17,147
16,323
Net income
$
28,224
$
53,051
$
126,230
$
152,853
(1) Excludes restructuring and other expenses and merger and acquisition related expenses
(2) Excludes merger and acquisition related expenses
(3) Excludes litigation expenses and merger and acquisition related expenses
(4) The Company excludes these expenses in order to provide better comparability between periods as they are not representative of the Company's ongoing operations.
Depreciation expense is a significant expense related to research and development expenses, sales and marketing expenses and general and administrative expenses as shown above. For the three and nine months ended September 27, 2025 , depreciation expense was $ 5.0 million and $ 15.2 million, respectively. For the three and nine months ended September 28, 2024 , depreciation expense was $ 3.9 million and $ 10.8 million, respectively.
The following table lists the different sources of revenue:
Three Months Ended
Nine Months Ended
September 27,
September 28,
September 27,
September 28,
2025
2024
2025
2024
(in thousands, except for percentages)
Systems and software
$
173,795
80
%
$
217,135
86
%
$
619,451
84
%
$
622,400
86
%
Parts
23,930
11
%
19,995
8
%
61,955
8
%
56,890
8
%
Services
20,468
9
%
15,080
6
%
56,991
8
%
44,092
6
%
Total revenue
$
218,193
100
%
$
252,210
100
%
$
738,397
100
%
$
723,382
100
%
20
Table of Contents
The Company’s significant operations outside the United States include sales, service and application offices in Asia and Europe. For geographical revenue reporting, revenue is attributed to the geographic location to which the product is shipped. Revenue by geographic region is as follows:
Three Months Ended
Nine Months Ended
September 27,
September 28,
September 27,
September 28,
2025
2024
2025
2024
(in thousands)
Revenue from third parties:
Taiwan
$
59,243
$
78,273
$
227,441
$
209,006
South Korea
44,864
77,014
220,828
227,958
United States
37,793
21,979
90,946
61,763
Japan
16,015
12,559
58,152
45,172
China
27,359
32,112
56,872
86,222
Southeast Asia
22,329
15,589
44,179
55,796
Europe
10,590
14,684
39,979
37,465
Total revenue
$
218,193
$
252,210
$
738,397
$
723,382
The following customers accounted for 10% or more of total revenue for the indicated periods:
Nine Months Ended
September 27,
September 28,
2025
2024
Customer A
21
%
19
%
Customer B
18
%
20
%
Customer C
14
%
13
%
Three customers’ net accounts receivable balances were individually greater than 10 % of net accounts receivable at September 27, 2025, representing, in the aggregate approximately 46 % of the Company’s total net accounts receivable.
Two customers’ net accounts receivable balances were individually greater than 10 % of net accounts receivable at December 28, 2024 , representing, in the aggregate, approximately 47 % of the Company’s total net accounts receivable.
Substantially all of the Company’s long-lived assets are located within the United States of America.
NOTE 16. Share Repurchase Authorization
In February 2024, the Onto Innovation Board of Directors approved a new share repurchase authorization, which allows the Company to repurchase up to $ 200 million worth of shares of its common stock. Repurchases may be made through both public market and private transactions from time to time. Any amount paid to repurchase the shares in excess of par value, including transaction costs, would be recorded directly as a decrease to additional paid-in capital and accumulated earnings. During the three and nine months ended September 27, 2025, 0 and 492 thousand shares of the Company’s common stock were repurchased under the share repurchase authorization, respectively. At September 27, 2025 , there was $ 99.9 million available for future share repurchases under this share repurchase authorization.
NOTE 17. Restructuring and Other
From time to time, the Company approves restructuring plans, which include workforce reductions, to streamline operations and align the Company’s cost structure with its business outlook. These restructuring plans may result in charges to cost of goods sold for streamlining of certain manufacturing activities and other charges, including inventory write-downs primarily related to the exit of older product lines. Charges to operating expenses primarily include employee severance costs
21
Table of Contents
that are paid during the period incurred, charges for streamlining of certain operating activities and impairment charges such as plant, property and equipment.
Restructuring and other expenses recorded in the Condensed Consolidated Statements of Operations are as follows:
Three Months Ended
Nine Months Ended
September 27,
September 28,
September 27,
September 28,
2025
2024
2025
2024
(in thousands)
Cost of goods sold
$
7,303
$
1,084
$
27,129
$
2,575
Operating expenses
4,074
2,167
11,421
3,046
Total restructuring and other
$
11,377
$
3,251
$
38,550
$
5,621
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.